Consultation recommendations |
Consultation
recommendations |
2018 |
2019 |
2020 |
Number of anti-infection recommendations n (%) |
Empirical application |
25(18.0) |
50(18.9) |
56(17.1) |
|
Drug use adjustment |
60(43.2) |
126(47.5) |
153(46.6) |
|
Whether to apply antibacterial drugs |
6(4.3) |
11(4.2) |
23(7.0) |
|
Whether to deactivate antibacterial drugs |
3(2.2) |
18(6.8) |
22(6.7) |
|
Preventive use |
1(0.7) |
1(0.4) |
2(0.6) |
|
Dosage adjustment |
19(13.7) |
18(6.8) |
30(9.1) |
|
Treatment course |
7(5.0) |
7(2.6) |
9(2.7) |
|
Other recommendations |
18(12.9) |
34(12.8) |
33(10.1) |
|
Total |
139(100) |
265(100) |
328(100) |
Number of anticoagulant recommendations n (%) |
Empirical application |
2(16.7) |
3(7.7) |
12(14.5) |
|
Drug use adjustment |
1(8.3) |
1(2.6) |
5(6.0) |
|
Dosage selection |
2(16.7) |
6(15.4) |
7(8.4) |
|
Treatment course |
1(8.3) |
1(2.6) |
3(3.6) |
|
Whether to apply anticoagulant drug |
1(8.3) |
8(20.5) |
22(26.5) |
|
Whether to deactivate antibacterial drug |
3(25.0) |
6(15.4) |
7(8.4) |
|
Physical method |
1(8.3) |
12(30.8) |
24(28.9) |
|
Other recommendations |
1(8.3) |
2(5.1) |
3(3.6) |
|
Total |
12(100) |
39(100) |
83(100) |
Number of PPIs application recommendations n (%) |
Whether to apply
PPIs |
1(8.3) |
5(17.2) |
13(25.0) |
|
Choice of drugs |
3(25.0) |
8(27.6) |
9(17.3) |
|
Preventive use |
4(33.3) |
7(24.1) |
16(30.8) |
|
Dose adjustment |
2(16.7) |
7(24.1) |
9(17.3) |
|
Treatment course |
1(8.3) |
1(3.4) |
1(1.9) |
|
Other recommendations |
1(8.3) |
1(3.4) |
4(7.7) |
|
Total |
12(100) |
29(100) |
52(100) |
Number of nutritional support recommendations n (%) |
enteral |
2(66.7) |
17(81.0) |
18(62.1) |
|
parenteral |
1(33.3) |
4(19.0) |
11(37.9) |
|
Total |
3(100) |
21(100) |
29(100) |
Number of follow-up monitoring recommendations n (%) |
Liver and kidney
function |
32(25.8) |
58(21.2) |
90(21.7) |
|
Coagulation index |
6(4.8) |
28(10.3) |
62(15.0) |
|
Infection index/signs |
73(58.9) |
136(49.8) |
202(48.8) |
|
Bleeding |
2(1.6) |
10(3.7) |
29(7.0) |
|
Nutrition improvement |
3(2.4) |
15(5.5) |
19(4.6) |
|
Adverse reactions |
8(6.5) |
26(9.5) |
12(2.9) |
|
Total |
124(100) |
273(100) |
414(100) |
Total(n) |
|
290 |
627 |
906 |